Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Annals of Hematology|March 25, 2017
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myelomaMuhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2013
Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigenSoung-Chul Cha, Hong Qin, Shibichakravarthy Kannan, et al.
Nature Medicine|March 5, 2013
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletionYared Hailemichael, Zhimin Dai, Nina Jaffarzad, et al.
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2012
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanomaJahan S Khalili, Shujuan Liu, Tania G Rodríguez-Cruz, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
The Journal of Infectious Diseases|July 19, 2024
Reduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 VariantMatthew E Levy, Vanessa Chilunda, Richard E Davis, et al.
Science Translational Medicine|May 31, 2019
Reprogrammed marrow adipocytes contribute to myeloma-induced bone diseaseHuan Liu, Jin He, Su Pin Koh, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Pageof 13